More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 769 9200 UK: +44 (0)20 7769 6464 GER: +49 (0)69 254 99300 Conference ID: 2545624 To avoid waiting time, please join the event co

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem New software capabilities support standardized analysis and reporting across digital PCR workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across li

Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories QIAGEN's broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts

New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information Expands QIAGEN's digital ecosystem with AI-driven workflow support embedded directly into the customer experience QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and man

Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms, therapeutic targets and biomarkers are identified Graph-based AI approach designed to help researchers explore mechanisms, therapeutic targets and biomarkers with greater speed, context and confidence Initial pilot programs available to select pharmaceutical and biotechnology partners, with broader availability in future stages following validation QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insigh

Co-founder and former CEO Dr. Metin Colpan to become Honorary Chairman of the Supervisory Board after deciding not to stand for re-election Robert McMahon nominated for election to Supervisory Board as part of ongoing renewal process, with seven of eight proposed members having joined since 2021 40% increase in annual dividend proposed to $0.35 per share, reflecting continued commitment to increasing returns to shareholders Additional share repurchase authorizations, including authorization for further open-market share repurchases and a new $200 million synthetic share repurchase Thierry Bernard to stand for re-election as Managing Board member until a new CEO has been app

Ambition to support high-throughput laboratories in efficiently scaling latent tuberculosis (TB) screening as testing volumes continue to grow Fully automated workflow targeted for late 2027 launch integrates QuantiFERON test, Diasorin LIAISON systems, and purpose-built end-to-end automation from new Inpeco partnership AI-enabled risk stratification tool for TB progression targeted for late 2027 launch, designed to support all QuantiFERON customers with informed clinical decision-making for patient care QIAGEN and Diasorin driving LIAISON adoption with LIAISON QuantiFERON-TB Gold Plus II, designed to deliver significant throughput and workflow benefits in the U.S. and Europe

Q1 2026 results in line with pre-announcement: Net sales rise 2% to $492 million on a reported basis, and -1% at constant exchange rates (CER) vs. outlook for at least 1% CER growth Sample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand Diluted EPS of $0.33; adjusted diluted EPS of $0.54, also $0.54 CER in line with outlook Adjusted operating income margin at 27.4%, as ongoing high level of profitability absorbs Parse investments and headwinds from tariffs and currency movements Updated full-year 2026 outlook reconfirmed: Net sales growth of about 1-2% CER and adj. diluted EPS of at least $2.

SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)

20-F - QIAGEN N.V. (0001015820) (Filer)

IRANNOTICE - QIAGEN N.V. (0001015820) (Filer)

SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)

6-K - QIAGEN N.V. (0001015820) (Filer)

25-NSE/A - QIAGEN N.V. (0001015820) (Subject)

25-NSE - QIAGEN N.V. (0001015820) (Subject)

6-K - QIAGEN N.V. (0001015820) (Filer)

SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)

6-K - QIAGEN N.V. (0001015820) (Filer)

Berenberg downgraded Qiagen from Buy to Hold and set a new price target of $45.50

Kepler initiated coverage of Qiagen with a rating of Hold and set a new price target of $38.60

Morgan Stanley upgraded Qiagen from Equal-Weight to Overweight and set a new price target of $42.00

Robert W. Baird upgraded Qiagen from Neutral to Outperform and set a new price target of $43.00

Barclays downgraded Qiagen from Overweight to Equal Weight and set a new price target of $44.00

Deutsche Bank upgraded Qiagen from Hold to Buy and set a new price target of $54.00

Deutsche Bank downgraded Qiagen from Buy to Hold and set a new price target of $54.00

Citigroup downgraded Qiagen from Buy to Neutral and set a new price target of $50.00

Barclays initiated coverage of Qiagen with a rating of Overweight and set a new price target of $55.00

Redburn Atlantic downgraded Qiagen from Buy to Neutral

SC 13G - QIAGEN N.V. (0001015820) (Subject)

SC 13G/A - QIAGEN N.V. (0001015820) (Subject)

SC 13G/A - QIAGEN N.V. (0001015820) (Subject)

SC 13G/A - QIAGEN N.V. (0001015820) (Subject)

SC 13G/A - QIAGEN N.V. (0001015820) (Subject)

SC 13G/A - QIAGEN N.V. (0001015820) (Subject)

SC 13G/A - QIAGEN N.V. (0001015820) (Subject)

Co-founder and former CEO Dr. Metin Colpan to become Honorary Chairman of the Supervisory Board after deciding not to stand for re-election Robert McMahon nominated for election to Supervisory Board as part of ongoing renewal process, with seven of eight proposed members having joined since 2021 40% increase in annual dividend proposed to $0.35 per share, reflecting continued commitment to increasing returns to shareholders Additional share repurchase authorizations, including authorization for further open-market share repurchases and a new $200 million synthetic share repurchase Thierry Bernard to stand for re-election as Managing Board member until a new CEO has been app

QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026. In addition, Prof. Dr. Ross Levine has stepped down from the Supervisory Board also on January 23, 2026, following his appointment to a new leadership role as Chief Scientific Officer at Memorial Sloan Kettering Cancer Center. He will continue to serve as Chair of the QIAGEN Scientific Advisory Board. "We are pleased to welcome Mark Stevenson to our Supervisory Board," said Stephen H. Rusckowski, Chairman of the Supervisory Board. "Ma

Return of approximately $500 million – maximum approved by shareholders – set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS QIAGEN delivers well ahead of schedule on its commitment to return at least $1 billion through end-2028, considering additional ways to increase returns in 2026 and beyond QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced details for completion of plans to return approximately $500 million to shareholders through a synthetic share repurchase that combines a direct capital repayment

QIAsymphony Connect, the next generation of automated nucleic acid purification platform, to be shown at AMP 2025 as early access phase begins ahead of full release in mid-2026 QIAGEN showcases Sample to Insight workflows for comprehensive genomic profiling (CGP) based on Element Biosciences Trinity™ technology Partnership with Myriad Genetics Inc. to highlight development of a homologous recombination deficiency (HRD) assay for use in cancer profiling QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN's widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for

LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its

BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors.   Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer."Chan has significant experience advancing novel cancer

JERSEY, Channel Islands, Oct. 05, 2021 (GLOBE NEWSWIRE) --  Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company's Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it continues to expand globally. "I am delighted to welcome a strong and experienced commercial leader like Mohammad to the Executive team. During the last 30 years, he has been partnering with customers across the globe. Mohammad will be instrumental in accelerating the commercialization of our MosaiQ solution. He will continue to build the commercial team and expand the distribution channels whil

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect. Mr. Ebeling joins QIAGEN as part of a process launched by the Supervisory Board in 2020 to further complement and enhance the Board’s already extensive experience in Life Sciences and diagnostics. The addition of Mr. Ebeling brings the number of current Supervisory Board members to eight. “On behalf of the Supervisory Board and Managing Board, I would like to welcome Th

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United

QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 769 9200 UK: +44 (0)20 7769 6464 GER: +49 (0)69 254 99300 Conference ID: 2545624 To avoid waiting time, please join the event co

New CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers from positive blood cultures Together with the BCID GPF Plus AMR Panel, QIAstat-Dx now detects 33 pathogen targets and 28 antimicrobial resistance markers for comprehensive bloodstream infection testing QIAstat-Dx delivers results in about one hour to support patient management, antimicrobial stewardship and infection control efforts Builds on comprehensive offering for respiratory, gastrointestinal and meningitis / encephalitis panels as R&D continues on further menu expansion QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem New software capabilities support standardized analysis and reporting across digital PCR workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across li

Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories QIAGEN's broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts

New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface Natural-language experience helps reduce time spent searching across systems and connects customers more quickly to relevant QIAGEN information Expands QIAGEN's digital ecosystem with AI-driven workflow support embedded directly into the customer experience QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the global launch of QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify suitable products, access technical information and man

Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms, therapeutic targets and biomarkers are identified Graph-based AI approach designed to help researchers explore mechanisms, therapeutic targets and biomarkers with greater speed, context and confidence Initial pilot programs available to select pharmaceutical and biotechnology partners, with broader availability in future stages following validation QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insigh

Ambition to support high-throughput laboratories in efficiently scaling latent tuberculosis (TB) screening as testing volumes continue to grow Fully automated workflow targeted for late 2027 launch integrates QuantiFERON test, Diasorin LIAISON systems, and purpose-built end-to-end automation from new Inpeco partnership AI-enabled risk stratification tool for TB progression targeted for late 2027 launch, designed to support all QuantiFERON customers with informed clinical decision-making for patient care QIAGEN and Diasorin driving LIAISON adoption with LIAISON QuantiFERON-TB Gold Plus II, designed to deliver significant throughput and workflow benefits in the U.S. and Europe

Q1 2026 results in line with pre-announcement: Net sales rise 2% to $492 million on a reported basis, and -1% at constant exchange rates (CER) vs. outlook for at least 1% CER growth Sample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand Diluted EPS of $0.33; adjusted diluted EPS of $0.54, also $0.54 CER in line with outlook Adjusted operating income margin at 27.4%, as ongoing high level of profitability absorbs Parse investments and headwinds from tariffs and currency movements Updated full-year 2026 outlook reconfirmed: Net sales growth of about 1-2% CER and adj. diluted EPS of at least $2.

Sample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio. For Q1 2026, preliminary net sales were $492 million, up 2% on a reported basis and down 1% at constant exchange rates (CER) compared with the outlook for at least 1% CER g